{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:35:30Z","timestamp":1789389330875,"version":"build-2803163510"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Youcare Pharmaceutical Group Co, Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Aildenafil citrate is a potent and selective inhibitor of cyclic guanosine monophosphate\u2013specific phosphodiesterase type 5, developed for the treatment of erectile dysfunction (ED).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This study aimed to assess the pharmacokinetics, safety, and tolerability of aildenafil citrate tablets after multiple doses in healthy Chinese males.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty participants were divided into 2 groups, 10 participants each. Participants were administered multiple doses of aildenafil citrate tablets at 30\u00a0and 60\u00a0mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>The safety evaluation was based on clinical symptoms and adverse events. Concentrations of aildenafil and its key metabolites (M1, M5, and M12) in human serum were measured by liquid chromatography\u2013tandem mass spectrometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Pharmacokinetic analysis showed rapid absorption and elimination of aildenafil, with a median time to maximum serum concentration of 1\u00a0hour and mean terminal half-lives of 2.75\u00a0and 3.26\u00a0hours in the respective dose groups. The mean maximum concentration was proportional to the aildenafil dose in the range of 30\u00a0to 60\u00a0mg, although the area under the curve was not proportional for serum concentration vs time 0 to the last measurable time point (24 hours). Multiple doses of aildenafil were well tolerated, with 60.0% of men experiencing treatment-emergent adverse events, notably myalgia and fatigue, particularly in the 60-mg group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Aildenafil citrate tablets demonstrated favorable tolerability with once-daily administration over the clinical dose range. The occurrence of myalgia and fatigue was more prevalent in the 60-mg group. From a pharmacokinetic perspective, optimal administration of aildenafil citrate tablets appears to be 1\u00a0hour before sexual intercourse in men with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>This study presents robust safety and pharmacokinetic data at expected therapeutic doses, unaffected by clinical factors. The efficacy of aildenafil citrate tablets warrants further validation in individuals with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Aildenafil citrate tablets exhibited good tolerability in healthy Chinese males following multiple doses at 30\u00a0and 60\u00a0mg. The 60-mg group showed an increased incidence of myalgia and fatigue, suggesting the need for heightened clinical vigilance. The mean maximum concentration, but not the area under the curve, displayed dose proportionality within the 30- to 60-mg dose range, and no significant drug accumulation was observed with repeated daily administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>CTR20192473 (http:\/\/www.chinadrugtrials.org.cn).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sexmed\/qfae008","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T06:02:17Z","timestamp":1710396137000},"source":"Crossref","is-referenced-by-count":4,"title":["Safety, tolerability, and pharmacokinetics of aildenafil citrate tablets, a novel oral PDE5 inhibitor, in healthy Chinese volunteers after multiple-dose administration"],"prefix":"10.1093","volume":"12","author":[{"given":"Ran","family":"Xie","sequence":"first","affiliation":[{"name":"Peking University First Hospital Department of Pharmacy, , Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jia","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pharmacy, , Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pharmacy, , Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pharmacy, , Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"He","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pharmacy, , Beijing 100034, China"},{"name":"Peking University First Hospital Institute of Clinical Pharmacology, , Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[{"name":"Research and Development Center, Youcare Pharmaceutical Group Co, Ltd , Beijing 100176, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pharmacy, , Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[{"name":"Peking University First Hospital Department of Pharmacy, , Beijing 100034, China"},{"name":"Peking University First Hospital Institute of Clinical Pharmacology, , Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"10","key":"2024031406020862600_ref1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s11255-017-1644-5","article-title":"Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis","volume":"49","author":"Gong","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"2024031406020862600_ref2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/iju.14785","article-title":"Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction: a randomized, double blind, multicenter clinical trial","volume":"29","author":"Kumar","year":"2022","journal-title":"Int J Urol"},{"key":"2024031406020862600_ref3","doi-asserted-by":"crossref","first-page":"111128","DOI":"10.1016\/j.biopha.2020.111128","article-title":"Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors","volume":"134","author":"Ahmed","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2024031406020862600_ref4","first-page":"151","article-title":"Clinical monograph for drug formulary review: erectile dysfunction agents","volume":"11","author":"Campbell HE","year":"2005","journal-title":"J Manag Care Pharm"},{"issue":"suppl 1","key":"2024031406020862600_ref5","first-page":"45S","article-title":"A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction","volume":"53","author":"Milligan","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"2024031406020862600_ref6","volume-title":"National Medical Products Administration Evaluation Center, Marketed drug information"},{"issue":"6","key":"2024031406020862600_ref7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2174\/138920010791636185","article-title":"Systematic evaluation of dose proportionality studies in clinical pharmacokinetics","volume":"11","author":"Sheng","year":"2010","journal-title":"Curr Drug Metab"},{"issue":"1","key":"2024031406020862600_ref8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm Stat"},{"issue":"4","key":"2024031406020862600_ref9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.urology.2009.04.026","article-title":"Oral sildenafil citrate (Viagra) for erectile dysfunction: a systematic review and meta-analysis of harms","volume":"74","author":"Tsertsvadze","year":"2009","journal-title":"Urology"},{"issue":"6","key":"2024031406020862600_ref10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/andr.12683","article-title":"The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue","volume":"7","author":"Zucchi","year":"2019","journal-title":"Andrology"},{"issue":"suppl 1","key":"2024031406020862600_ref11","first-page":"5S","article-title":"Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality","volume":"53","author":"Nichols","year":"2002","journal-title":"Br J Clin Pharmacol"}],"container-title":["Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/smoa\/article-pdf\/12\/1\/qfae008\/56966179\/qfae008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/smoa\/article-pdf\/12\/1\/qfae008\/56966179\/qfae008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T06:02:35Z","timestamp":1710396155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/smoa\/article\/doi\/10.1093\/sexmed\/qfae008\/7628339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/sexmed\/qfae008","relation":{},"ISSN":["2050-1161"],"issn-type":[{"value":"2050-1161","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2024,2,1]]},"article-number":"qfae008"}}